Nisus Finance Services Co. Ltd. (NISUS)

Overview

Jupiter Neurosciences, Inc. is an innovative clinical-stage research and development pharmaceutical company focused on the creation of resveratrol platform products, chiefly aimed at treating neuroinflammation. The company's strategies revolve around developing groundbreaking treatments for various neurological ailments by leveraging the therapeutic potentials of resveratrol. Originally founded in 2015 as Jupiter Orphan Therapeutics, Inc., it underwent a name change to Jupiter Neurosciences, Inc. in August 2021 to better reflect its dedication to neurological research. With its headquarters strategically positioned in Jupiter, Florida, Jupiter Neurosciences has been at the forefront of addressing some of the most challenging neurological diseases through its extensive research and development programs.

Products and Services

Jupiter Neurosciences, Inc. is currently advancing a diverse portfolio of products, each at various stages of clinical trials, specifically targeting a range of debilitating neurological conditions:

• JNS101 in Phase II trial for Friedreich's Ataxia: This promising treatment is currently under investigation for its potential in addressing Friedreich's Ataxia, a rare genetic disease that affects the nervous system and causes movement difficulties. Jupiter Neurosciences is exploring the efficacy of JNS101 in mitigating the symptoms and progression of this debilitating condition.
• JNS108 in Phase II trial for Mild Cognitive Impairment/Early Alzheimer's Disease: Alzheimer's disease, characterized by cognitive decline, poses a significant challenge in neurodegenerative disease management. JNS108 is being studied for its potential to slow down or halt the early stages of cognitive impairment associated with Alzheimer’s, offering hope to patients and caregivers alike.
• JNS102 in Phase II trial for Mucopolysaccharidosis Type 1: This enzyme replacement therapy aims to treat mucopolysaccharidosis type 1, a rare lysosomal storage disorder. By targeting the underlying cause of the disease, JNS102 seeks to improve the quality of life for patients suffering from this condition.
• JNS107 in Phase II trial for Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) Syndrome: Jupiter Neurosciences is developing JNS107 as a treatment option for MELAS syndrome, a rare mitochondrial disorder that leads to a range of serious complications. This trial seeks to evaluate the efficacy of JNS107 in managing the diverse symptoms associated with the syndrome.
• JNS115 in Phase II trial for Parkinson's Disease: Parkinson's disease, known for its impact on movement, is another area of focus for Jupiter Neurosciences. JNS115 is under investigation for its potential to offer symptomatic relief and to possibly slow the progression of the disease, providing new hope for patients and families.